Elotuzumab Plus Bortezomib Active in Relapsed/Refractory Multiple Myeloma

Share this content:

(ChemotherapyAdvisor) – The combination of elotuzumab plus bortezomib showed encouraging activity in patients with relapsed/refractory multiple myeloma, a phase I study published in the Journal of Clinical Oncology online January 30 has found.

The trial enrolled 28 patients with relapsed/refractory multiple myeloma who had received ≤3 prior therapies (median=2) for their disease. Three patients each received 2.5, 5.0, and 10mg/kg IV elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody, on days 1 and 11 and bortezomib 1.3mg/m2 IV on days 1, 4, 8, and 11 in 21-day cycles.

The maximum-tolerated dose was not reached up to the maximum planned dose of 20mg/mg, reported Andrzej J. Jakubowiak, MD, PhD, University of Chicago Medical Center, Chicago, IL, and colleagues; an additional 19 patients received elotuzumab 20mg/kg, 6 during dose escalation and 13 during an expansion phase.

An objective response of partial response or better was observed in 13 of 27 evaluable patients (48%), including 2 of 3 refractory to bortezomib. Median time to progression was 9.46 months. The most frequent grade 3/4 adverse events (AEs) were lymphopenia in 25% of patients and fatigue in 14%. One patient had elotuzumab-related serious AEs of chest pain and gastroenteritis.

The investigators report a phase 3 study of elotuzumab in combination with lenalidomide and dexamethasone in relapsed multiple myeloma is ongoing.

Clinical Trial

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs